We aim to create new technologies that enhance the efficacy and safety of future regenerative medicine products. The Core Groups have excellent track records in this field with high quality publications (2012 examples include Nature Biotech 30, 808; Lancet 380, 507, PNAS 109, 14070 and Nature Communications 673, 10.1038) and extensive translational activities.

The core team will generate platform technologies that are specified by our pre-clinical spokes and industrial end-users.

Our core team is composed of materials scientists and stem cell biologists from University of Nottingham, Imperial College, University of Manchester, Keele University and Southampton University. These teams have experience in the design of advanced materials for medical applications.

Director: Professor Kevin Shakesheff, University of Nottingham

Co-Director: Professor Molly Stevens, Imperial College London

Hub Leads:

Our researchers: